Prediction of Response to Chemotherapy in Patients with Osteosarcoma and Ewing’s Sarcoma
Lousika Bokacheva1, Ya Wang1, Wei Huang2, David M. Panicek3, and Jason A. Koutcher1,2

1Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States, 2Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, United States, 3Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Introduction
Osteosarcoma (OS) and Ewing’s sarcoma (ES) are aggressive bone cancers found primarily in pediatric patients. The standard of care for nonmetastatic OS and ES includes neoadjuvant chemotherapy followed by surgery providing 60–70% long-term survival. MRI has shown promise in predicting early response to chemotherapy in patients with OS [1]. The purpose of this study was to assess the ability of DCE MRI to predict the histological response to chemotherapy in patients with OS and ES.

Methods
This prospective, HIPAA-compliant study was approved by the Institutional Review Board and informed consent was obtained from all patients. Between 2004 and 2010, patients were enrolled into the study if they were recently diagnosed with osteosarcoma (OS) or Ewing’s sarcoma (ES) and received no prior treatment. Each patient underwent MRI before, during, and after the completion of chemotherapy (MRI1, MRI2, MRI3, respectively) followed by surgery or radiation therapy (RT). In patients who underwent surgery, tumors were histologically analyzed and percent necrosis was determined on a central slice. Follow-up was established based on the results of the last clinical examination (up to 6 years after imaging). MRI was performed at 1.5 T (Signa Excite; GE Healthcare, Waukesha, WI) and included anatomical sequences followed by T1-weighted DCE MRI (SPGR sequence; TR = 7–9 ms; TE = 1.7–1.9 ms; acquired matrix 256x128 interpolated to 256x256; field of view, 24x24 cm² to 50x50 cm²; slice thickness/gap, 9–13 mm; number of slices, 6–11; number of time points, 40–60; number of pre-contrast images 5–10; temporal resolution, 10 s. DCE series was acquired after an injection of 0.2 mmol/kg gadolinium dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals, Wayne, NJ) over 6–10 min. Image analysis was performed in Matlab (Mathworks, Natick, NJ). Voxelwise enhancement was converted to change in relaxivity using the Tofts model [3] with two parameters (Ktrans and vve) implemented in linearized form [4] and the appropriately scaled population-based arterial input function (AIF) from literature [5]. Regions of interest were drawn around the tumor on all slices and the mean parameters were obtained and were compared across the time points using Wilcoxon signed-rank test and between subsets of the data using Mann-Whitney U-test. The correlations between model parameters and histological percent necrosis were assessed using Spearman’s correlation coefficient ρ.

Results
A total of 37 patients with leg tumors were included into the study; three patients were excluded because of motion artifacts (n=2) or lack of tumor enhancement (n=1). Among the final 34 patients, 28 had OS and 6 had ES. Femur was the most common tumor site (n=23), followed by tibia (n=9) and other locations (n=2). The median age of the patients was 13 years (range, 7–30 years). All patients except one were treated with chemotherapy and surgery; one patient received no prior treatment. Each patient received ≥6 cycles of chemotherapy. The median interval between the start of chemotherapy and surgery was 12 weeks (range, 9–17 weeks). By the end of the study, 28/34 patients who underwent surgery, tumors were histologically analyzed and percent necrosis was determined on a central slice. Follow-up was established based on the results of the last clinical examination (up to 6 years after imaging). MRI was performed at 1.5 T (Signa Excite; GE Healthcare, Waukesha, WI) and included anatomical sequences followed by T1-weighted DCE MRI (SPGR sequence; TR = 7–9 ms; TE = 1.7–1.9 ms; acquired matrix 256x128 interpolated to 256x256; field of view, 24x24 cm² to 50x50 cm²; slice thickness/gap, 9–13 mm; number of slices, 6–11; number of time points, 40–60; number of pre-contrast images 5–10; temporal resolution, 10 s. DCE series was acquired after an injection of 0.2 mmol/kg gadolinium dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals, Wayne, NJ) over 6–10 min. Image analysis was performed in Matlab (Mathworks, Natick, NJ). Voxelwise enhancement was converted to change in relaxivity using the Tofts model [3] with two parameters (Ktrans and vve) implemented in linearized form [4] and the appropriately scaled population-based arterial input function (AIF) from literature [5]. Regions of interest were drawn around the tumor on all slices and the mean parameters were obtained and were compared across the time points using Wilcoxon signed-rank test and between subsets of the data using Mann-Whitney U-test. The correlations between model parameters and histological percent necrosis were assessed using Spearman’s correlation coefficient ρ.

Table: Tofts model parameters derived from DCE MRI performed before, during and after chemotherapy (MRI1-3) and Wilcoxon test p-values for comparison between time points

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MRI1</th>
<th>MRI2</th>
<th>MRI3</th>
<th>p-value MRI 1 vs 2</th>
<th>p-value MRI 1 vs 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ktrans min⁻¹</td>
<td>0.081±0.029</td>
<td>0.067±0.039</td>
<td>0.050±0.031</td>
<td>0.083</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>vve</td>
<td>0.20±0.08</td>
<td>0.18±0.09</td>
<td>0.17±0.06</td>
<td>0.47</td>
<td>0.69</td>
</tr>
</tbody>
</table>

Discussion
The majority of patients showed a decrease in Ktrans values at the completion of chemotherapy. The percent decrease in Ktrans and the mean Ktrans at MRI3 were predictive of histological response, in agreement with Guo et al. [1]. However, the model parameters did not appear to be correlated with survival, possibly because of the small and heterogeneous dataset.

References